Inspire: Prolacria clinical trial did not meet expectations

DURHAM, N.C. An investigational drug for treating dry eye didn’t work as well as its developers hoped, according to late-stage clinical trial results released Thursday.

Inspire Pharmaceuticals conducted a 490-patient phase 3 trial of Prolacria (diquafosol tetrasodium) ophthalmic solution in patients with dry eye, measuring progress based on the fluorescein staining score of zero to three used by the National Eye Institute, with a score of zero indicating a clearing of the eye. Inspire said the trial failed to meet its respective primary and secondary goals of clearing the central region of the cornea and reducing staining score in patients receiving the drug compared with those receiving placebo.

“We have provided the top-line results from this trial to our partner Allergan, and we will be conducting a thorough review of the program before determining next steps, if any,” Inspire president and CEO Christy Shaffer said in a statement.